Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07485205

Establishing Normative Urodynamics Parameters for the Glean Urodynamics System in Healthy Adults

A prospective, open-label, single arm interventional trial to establish normative reference ranges for urodynamics parameters in healthy adult participants using using the Glean Urodynamics System.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Arizona Research Center, Phoenix, Arizona, United States

Loading trial locations.

About this study

Subjects will have the Glean Urodynamics System inserted for an in-clinic ambulatory monitoring period. Afterward, they will be discharged with the Glean Bladder Sensor in place for continued monitoring outside the clinic, not exceeding 24 hours. The sensor will be removed within 24 hours of insertion. Subjects will receive a follow-up phone call 7 days post-removal.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy male and female adults ages 18 to 45 years.
  • Patient is able to read, write, and communicate in English.
  • Patient is able to provide informed consent.
  • Patient owns, can independently operate, and is willing to use a smart device for study data collection purposes

Exclusion criteria

  • Patient with any prior pregnancy (gravida ≥1), is currently pregnant (as confirmed by urine pregnancy test or medical history), or intends to become pregnant during the study period.
  • Patient has one or more symptoms indicative of a symptomatic urinary tract infection (UTI) (i.e., fever, costovertebral angle pain or tenderness, suprapubic tenderness, worsening urinary frequency, worsening urgency, and/or dysuria).
  • Patient has a known history of urological conditions (e.g., recurrent UTIs, incontinence, symptomatic benign prostatic hyperplasia, neurogenic bladder, interstitial cystitis, urinary retention, any genitourinary cancer).
  • Patient has a known history of neurological conditions that can affect central nervous system function.
  • Patients with a current or prior diagnosis of diabetes mellitus (Type 1 or Type 2).
  • Patient is currently taking medications that may affect urological functions (e.g., diuretics, anticholinergics, alpha-blockers).
  • Patient has abnormal urinary habits if one or more of the following bladder events are reported on any day of the 3-day bladder diary: urinary frequency ≥ 8 times/day, ≥ 1 nocturia episode, ≥ 1 leak event, or ≥ 1 urgency event.
  • Patient has a total score on the Lower Urinary Tract Dysfunction Research Network Symptom Index-10 (LURN SI-10) questionnaire greater than 0; a total score of 1 is acceptable only if the sole positive response is urinary frequency of 4-7 times per day.
  • Patient has a urostomy and/or colostomy.
  • Patient has an atypical anatomic structural variation or has had a previous surgical intervention that has permanently changed structural anatomy anywhere along their lower urinary tract (urethra, pelvic floor, urethral sphincter, and/or bladder wall) that the principal investigator deems might compromise the placement or retention of the Glean sensors during the study (e.g., strictures).
  • Patient has a Pelvic Organ Prolapse Quantification (POP-Q) of Grade III or higher (i.e., most distal portion of the prolapse protrudes more than 1 centimeter below the hymen).
  • Patient would not be appropriate for this study as determined by the Principal Investigator.

Treatment and study plan

Glean Urodynamics System

Device

Glean Urodynamics System including a bladder pressure sensor, abdominal pressure sensor, in-clinic uroflowmeter, and software apps.

Primary outcomes

  1. Range of vesical pressure (Pves)

    Time frame: Periprocedurally

    Range of vesical pressure (Pves) in cm H2O as measured by the Glean Bladder Sensor

Study contacts

Contact information is provided by the study sponsor or research team.

Brittany Carter, DHSc, MPH

CONTACT

[email protected]

949-202-5689

Suranjan Roychowdhury, PhD

CONTACT

[email protected]

949-202-5685

Sponsors and collaborators

Lead sponsor

Bright Uro

Industry

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Mar 20, 2026
Registry last updated
Jul 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.